Date published: 2025-10-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

PLEKHA4 Activators

PLEKHA4 activators comprise a chemical class that specifically targets and increases the activity of the PLEKHA4 protein, which is a pleckstrin homology domain-containing protein. The activation of PLEKHA4 by these compounds can modulate the protein's involvement in various cellular processes, such as signal transduction pathways, cytoskeletal organization, and membrane dynamics. The precise mechanisms of action for these activators can vary, but generally, they interact with the protein in a way that enhances its ability to engage with its natural substrates or binding partners. This interaction can lead to an augmented downstream signaling effect, which can alter cellular behavior in line with the role that PLEKHA4 plays within the cell.

Unlike inhibitors, activators function to up-regulate or increase the activity of their target proteins. The chemical structures of PLEKHA4 activators are diverse and can include small molecules that bind to allosteric sites, thereby inducing a conformational change that increases the protein's activity. Alternatively, some compounds may act as mimetics of natural binding partners or substrates, binding to the active site of PLEKHA4 and facilitating its interaction with other proteins or lipids. While the direct binding of activators to PLEKHA4 can lead to an immediate increase in protein activity, other compounds may indirectly enhance PLEKHA4 activity by stabilizing the protein, protecting it from degradation, or facilitating its localization to specific cellular compartments where it is active. These activators are of interest in the study of cellular signaling and protein-protein interactions

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin is a steroidal metabolite of the fungi Penicillium funiculosum that can inhibit phosphoinositide 3-kinases (PI3K), which indirectly affects PLEKHA4-related signaling pathways.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 is a synthetic molecule that can inhibit PI3K, thereby affecting pathways that include PLEKHA4.

GSK 2334470

1227911-45-6sc-364501
sc-364501A
10 mg
50 mg
$195.00
$1142.00
1
(0)

GSK2334470 is a selective inhibitor of 3-phosphoinositide-dependent protein kinase-1 (PDK1), potentially affecting PLEKHA4 downstream signaling.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

Staurosporine is an alkaloid that can inhibit a broad spectrum of protein kinases potentially influencing the activity of PLEKHA4.

Bisindolylmaleimide I (GF 109203X)

133052-90-1sc-24003A
sc-24003
1 mg
5 mg
$103.00
$237.00
36
(1)

Bisindolylmaleimide I is a selective inhibitor of protein kinase C (PKC) which may indirectly modulate PLEKHA4 activity through PKC-mediated pathways.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

U0126 can inhibit mitogen-activated protein kinase (MEK), and indirectly affect PLEKHA4-related signaling.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

SB203580 is a pyridinyl imidazole that can inhibit p38 MAP kinase, thus potentially affecting signaling pathways that involve PLEKHA4.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is an anthrapyrazolone inhibitor that can block c-Jun N-terminal kinase (JNK), influencing signaling pathways related to PLEKHA4.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

PD98059 can inhibit MEK, which could indirectly affect signaling pathways associated with PLEKHA4.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin is a macrolide compound that can inhibit mTOR, potentially impacting PLEKHA4-related signaling due to the role of mTOR in cell growth and proliferation.